Skip to main content
68°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zynerba Pharma CS
(NQ:
ZYNE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Zynerba Pharma CS
< Previous
1
2
3
4
5
6
7
8
9
Next >
Cannabis Stock Movers For July 10, 2023
July 10, 2023
Via
Benzinga
Why Theriva Biologics Are Trading Higher By Over 76%; Here Are 20 Stocks Moving Premarket
June 28, 2023
Gainers Theriva Biologics, Inc. (NYSE: TOVX) shares surged 76.4% to $1.46 in pre-market trading after the company said Orphan Drug Designation was granted by the U.S. Food and Drug Administration for...
Via
Benzinga
Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
June 27, 2023
Gainers
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 08, 2023
On Wednesday, 116 companies set new 52-week lows.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 27, 2023
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on Tuesday morning!
Via
InvestorPlace
Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details
May 15, 2023
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter...
Via
Benzinga
Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?
March 28, 2023
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for...
Via
Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
March 14, 2023
Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 26, 2023
On Wednesday, 345 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 10, 2023
On Friday, 497 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 06, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 24, 2023
On Friday, 135 companies reached new 52-week lows.
Via
Benzinga
ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders
February 20, 2023
Given the progress of its clinical trials, and its latest quarterly financials, Zynerba appears to be an excellent buy-and-hold investment consideration.
Via
Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
January 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 18, 2023
Via
Benzinga
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
January 11, 2023
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 06, 2022
Gainers
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
December 28, 2022
On Wednesday, 258 companies hit new 52-week lows.
Via
Benzinga
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
December 05, 2022
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
November 25, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 23, 2022
Via
Benzinga
Cannabis Legalization In Germany And Thailand, Gray Market In Brooklyn, Craft Weed Companies In Oregon
November 18, 2022
German Opposition Official Against Recreational Marijuana Legalization Plan
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 16, 2022
On Wednesday, 70 companies set new 52-week lows.
Via
Benzinga
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
November 14, 2022
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights
Via
Benzinga
A Comparison Of 5 Psychedelic ETFs And Indices
November 11, 2022
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector.
Via
Talk Markets
The Psychedelic Drug Stocks Index Continued To Plummet Last Week
November 07, 2022
In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD.
Via
Talk Markets
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
October 27, 2022
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD.
Via
Talk Markets
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
October 24, 2022
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.